Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

TRVI
Trevi Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 9, 2025 3:59:58 PM EDT
6.60USD0.000%(0.00)1,429,631
6.60Bid   6.63Ask   0.03Spread
Pre-market
May 9, 2025 9:28:30 AM EDT
7.00USD+6.061%(+0.40)3,313
After-hours
May 9, 2025 4:00:30 PM EDT
6.60USD-0.151%(-0.01)25,366
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
07:12AM EST  Trevi Expects To End Enrollment In Phase 2b/3 PRISM Trial For Pruritus Associated With PN By January 31, 2022   RTTNews
07:01AM EST  Trevi Therapeutics Announces Clinical Trial Updates For Lead Indications   Benzinga
Dec 16, 2021
04:06PM EST  Trevi Therapeutics to Attend Multiple Conferences in January 2022   PR Newswire
Nov 15, 2021
07:31AM EST  Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit   PR Newswire
Nov 11, 2021
06:43AM EST  Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $8   Benzinga
Nov 10, 2021
06:13PM EST  Trevi Therapeutics, Inc. - Common Stock Q3 EPS $(0.34) Beats $(0.40) Estimate   Benzinga
04:06PM EST  Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business   PR Newswire
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
07:31AM EST  Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference   PR Newswire
Nov 5, 2021
04:07PM EDT  Trevi Therapeutics Inc Files For Prospectus Relates To Resale From Time To Time Of Up To 5.6M Shares Of Common Stock By Selling Stockholder   Benzinga
Nov 3, 2021
04:06PM EDT  Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate   PR Newswire
Oct 13, 2021
04:05PM EDT  Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)   PR Newswire
Oct 11, 2021
06:08AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.55 A.M. EDT).   RTTNews
05:25AM EDT  Trevi Therapeutics Shares Rise 34% Premarket After Company Filed Friday to Withdraw its Offering of Shares   Benzinga
Oct 7, 2021
04:06PM EDT  Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech &   PR Newswire
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 30, 2021
06:57PM EDT  Trevi Therapeutics Announces $11.8 Million Private Placement Priced   PR Newswire
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 13, 2021
05:43AM EDT  Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $10   Benzinga
Aug 12, 2021
05:09PM EDT  Trevi Therapeutics Q2 EPS $(0.49) Misses $(0.48) Estimate   Benzinga
04:06PM EDT  Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business   PR Newswire
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
04:14AM EDT  Earnings Scheduled For August 12, 2021   Benzinga
Aug 9, 2021
04:06PM EDT  Trevi Therapeutics Announces Additions to the Senior Leadership Team   PR Newswire
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 5, 2021
04:06PM EDT  Trevi Therapeutics to Report Q2 2021 Financial Results on August 12   PR Newswire
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jun 21, 2021
04:26PM EDT  Trevi Therapeutics Reports In 8K Filing Lincoln Park Capital Entered Into Purchase Agreement Wherein The Co May Sell To Lincoln Park Capital Up To $15M Of Shares   Benzinga
Jun 9, 2021
07:30AM EDT  Trevi Therapeutics to Present at 2021 BIO Digital Conference   PR Newswire
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
04:06PM EDT  Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business   PR Newswire
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
04:06PM EDT  Trevi Therapeutics to Report Q1 2021 Financial Results on May 13   PR Newswire
Apr 7, 2021
07:30AM EDT  Trevi Therapeutics to Present at 20th Annual Needham Virtual   GlobeNewswire Inc
Mar 25, 2021
04:07PM EDT  Trevi Therapeutics Reports Q4 Net Loss Of $9.5M Compared To A Net Loss Of $6.5M YoY   Benzinga
04:05PM EDT  Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For March 25, 2021   Benzinga
Mar 18, 2021
04:05PM EDT  Trevi Therapeutics to Report Q4 and Year End 2020 Financial   GlobeNewswire Inc
Feb 18, 2021
04:05PM EST  Trevi Therapeutics to Present at 10th Annual SVB Leerink Global   GlobeNewswire Inc
Feb 1, 2021
07:37AM EST  Trevi Therapeutics Names William Forbes Chief Development Officer   RTTNews
07:30AM EST  Industry Veteran to Lead the Clinical Development of Haduvio in Multiple Indications   GlobeNewswire Inc
Nov 11, 2020
04:13PM EST  Trevi Therapeutics Reports Q3 Net Loss of $(7.378M) Vs. $(7.365M) In The Same Qtr. Last Year   Benzinga
04:05PM EST  PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis   GlobeNewswire Inc
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
07:30AM EST  Trevi Therapeutics to Present at Stifel Healthcare Conference   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 4, 2020
04:05PM EST  Trevi Therapeutics to Report Q3 2020 Financial Results on November 11   GlobeNewswire Inc
Oct 21, 2020
08:02AM EDT  Trevi Therapeutics Announces Resumption Of Patient Screening In Phase 2 Clinical Trial Of Haduvio For Chronic Cough In Patients With IPF   Benzinga
08:00AM EDT  Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF   GlobeNewswire Inc
Oct 13, 2020
04:05PM EDT  Trevi Therapeutics Announces the Hiring of Key Talent   GlobeNewswire Inc
Sep 9, 2020
04:05PM EDT  Trevi Therapeutics to Present at H.C. Wainwright Global Investment   GlobeNewswire Inc
Aug 14, 2020
09:34AM EDT  Trevi Therapeutics Yesterday Reported Q2 EPS $(0.41) Up From $(0.63) YoY   Benzinga
09:33AM EDT  Trevi Therapeutics Halted On Volatility; Shares Up 14%   Benzinga
05:18AM EDT  SVB Leerink Maintains Outperform on Trevi Therapeutics, Raises Price Target to $9   Benzinga
Aug 13, 2020
04:05PM EDT  Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Aug 11, 2020
10:56AM EDT  Shares of Trevi Therapeutics, Inc. (TRVI) are gaining nearly 30% on Tuesday morning despite no stock-related news to drive the shares.   RTTNews
Aug 5, 2020
07:30AM EDT  Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference   GlobeNewswire Inc
Jul 14, 2020
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga
Jul 13, 2020
02:42PM EDT  Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $12   Benzinga
07:34AM EDT  Trevi Therapeutics Announces Independent Data Monitoring Committee Recommends Continuation Of PRISM Trial With Expansion To 360 Subjects Per The Adaptive Design   Benzinga
07:30AM EDT  Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC